Do analysts recommend CELZ or GRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CELZ or GRTX more profitable?

Galera Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% Galera Therapeutics N/A N/A -99.34%

Do analysts rate NAII or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate CELZ or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is CELZ or TPST more profitable?

Creative Medical Technology's return on equity of -88.38% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% Tempest Therapeutics N/A -355.61% -121.21%

Do analysts rate GTBP or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is GTBP or CELZ more profitable?

GT Biopharma's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Creative Medical Technology N/A -88.38% -84.71%

Do analysts prefer CELZ or KALA?

KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 152,112.00%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts clearly believe KALA BIO is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CELZ or KALA more profitable?

Creative Medical Technology's return on equity of -88.38% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% KALA BIO N/A -1,336.10% -94.85%

Creative Medical Technology (CELZ) Competitors

$0.67 +0.02 (+2.42%)

As of 02:04 PM Eastern

Compare

CELZ vs. GRTX, NAII, TPST, GTBP, and KALA

Should you buy Creative Medical Technology stock or one of its competitors? MarketBeat compares Creative Medical Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creative Medical Technology include Galera Therapeutics (GRTX), Natural Alternatives International (NAII), Tempest Therapeutics (TPST), GT Biopharma (GTBP), and KALA BIO (KALA).

How does Creative Medical Technology compare to Galera Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Creative Medical Technology has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.6, suggesting that its share price is 160% more volatile than the broader market.

In the previous week, Galera Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 1 mentions for Galera Therapeutics and 0 mentions for Creative Medical Technology. Galera Therapeutics' average media sentiment score of 0.52 beat Creative Medical Technology's score of 0.00 indicating that Galera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Creative Medical Technology	Neutral
Galera Therapeutics	Positive

Creative Medical Technology has higher revenue and earnings than Galera Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	317.58	-$5.99M	-$2.14	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galera Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Galera Therapeutics	N/A	N/A	-99.34%

Summary

Galera Therapeutics beats Creative Medical Technology on 8 of the 12 factors compared between the two stocks.

How does Creative Medical Technology compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Creative Medical Technology (NASDAQ:CELZ) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Creative Medical Technology has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Creative Medical Technology	N/A	-88.38%	-84.71%

In the previous week, Natural Alternatives International's average media sentiment score of 0.00 equaled Creative Medical Technology'saverage media sentiment score.

Company	Overall Sentiment
Natural Alternatives International	Neutral
Creative Medical Technology	Neutral

32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Creative Medical Technology has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$141.87M	0.10	-$13.57M	-$2.39	N/A
Creative Medical Technology	$10K	317.58	-$5.99M	-$2.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Natural Alternatives International has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Summary

Creative Medical Technology beats Natural Alternatives International on 7 of the 12 factors compared between the two stocks.

How does Creative Medical Technology compare to Tempest Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Creative Medical Technology's return on equity of -88.38% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Tempest Therapeutics	N/A	-355.61%	-121.21%

In the previous week, Creative Medical Technology's average media sentiment score of 0.00 equaled Tempest Therapeutics'average media sentiment score.

Company	Overall Sentiment
Creative Medical Technology	Neutral
Tempest Therapeutics	Neutral

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Creative Medical Technology has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, meaning that its stock price is 272% less volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than Tempest Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	317.58	-$5.99M	-$2.14	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Summary

Creative Medical Technology beats Tempest Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Creative Medical Technology compare to GT Biopharma?

GT Biopharma (NASDAQ:GTBP) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

GT Biopharma's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Creative Medical Technology	N/A	-88.38%	-84.71%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, GT Biopharma's average media sentiment score of 0.00 equaled Creative Medical Technology'saverage media sentiment score.

Company	Overall Sentiment
GT Biopharma	Neutral
Creative Medical Technology	Neutral

GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than GT Biopharma. Creative Medical Technology is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Creative Medical Technology	$10K	317.58	-$5.99M	-$2.14	N/A

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Creative Medical Technology beats GT Biopharma on 6 of the 10 factors compared between the two stocks.

How does Creative Medical Technology compare to KALA BIO?

Creative Medical Technology (NASDAQ:CELZ) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 152,112.00%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts clearly believe KALA BIO is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Creative Medical Technology's return on equity of -88.38% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
KALA BIO	N/A	-1,336.10%	-94.85%

In the previous week, KALA BIO had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 1 mentions for KALA BIO and 0 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.00 equaled KALA BIO'saverage media sentiment score.

Company	Overall Sentiment
Creative Medical Technology	Neutral
KALA BIO	Neutral

Creative Medical Technology has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, indicating that its stock price is 326% less volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than KALA BIO. Creative Medical Technology is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	317.58	-$5.99M	-$2.14	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Summary

KALA BIO beats Creative Medical Technology on 7 of the 13 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.18M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.31	7.36	279.98	25.51
Price / Sales	317.58	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.33	17.18	11.15	6.35
Net Income	-$5.99M	-$12.52M	$3.48B	$347.60M
7 Day Performance	-9.02%	2.48%	2.51%	3.14%
1 Month Performance	-44.63%	-5.41%	-2.78%	-2.08%
1 Year Performance	-77.05%	51.14%	64.32%	21.27%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.0103 of 5 stars	$0.67 +2.4%	N/A	-77.4%	$3.18M	$10K	N/A	5
GRTX Galera Therapeutics	N/A	$0.09 flat	N/A	+282.6%	$14.12M	N/A	N/A	30	News Coverage
NAII Natural Alternatives International	0.5002 of 5 stars	$2.23 +0.5%	N/A	-39.3%	$14.00M	$129.86M	N/A	290
TPST Tempest Therapeutics	1.0384 of 5 stars	$0.87 -2.2%	N/A	-88.3%	$13.95M	N/A	N/A	20	Upcoming Earnings
GTBP GT Biopharma	0.1017 of 5 stars	$0.31 +3.4%	N/A	-83.0%	$13.83M	N/A	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. GRTX, NAII, TPST, GTBP, and KALA

How does Creative Medical Technology compare to Galera Therapeutics?

Summary

How does Creative Medical Technology compare to Natural Alternatives International?

Summary

How does Creative Medical Technology compare to Tempest Therapeutics?

Summary

How does Creative Medical Technology compare to GT Biopharma?

Summary

How does Creative Medical Technology compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. GRTX, NAII, TPST, GTBP, and KALA

How does Creative Medical Technology compare to Galera Therapeutics?

Do analysts recommend CELZ or GRTX?

Which has more risk and volatility, CELZ or GRTX?

Does the media refer more to CELZ or GRTX?

Which has preferable valuation and earnings, CELZ or GRTX?

Do institutionals & insiders believe in CELZ or GRTX?

Is CELZ or GRTX more profitable?

Summary

How does Creative Medical Technology compare to Natural Alternatives International?

Is NAII or CELZ more profitable?

Does the media prefer NAII or CELZ?

Do insiders and institutionals have more ownership in NAII or CELZ?

Which has higher earnings & valuation, NAII or CELZ?

Do analysts rate NAII or CELZ?

Which has more volatility and risk, NAII or CELZ?

Summary

How does Creative Medical Technology compare to Tempest Therapeutics?

Is CELZ or TPST more profitable?

Does the media refer more to CELZ or TPST?

Do institutionals & insiders believe in CELZ or TPST?

Do analysts rate CELZ or TPST?

Which has more volatility & risk, CELZ or TPST?

Which has better earnings & valuation, CELZ or TPST?

Summary

How does Creative Medical Technology compare to GT Biopharma?

Is GTBP or CELZ more profitable?

Do analysts rate GTBP or CELZ?

Does the media favor GTBP or CELZ?

Which has more risk and volatility, GTBP or CELZ?

Which has better earnings & valuation, GTBP or CELZ?

Do institutionals and insiders hold more shares of GTBP or CELZ?

Summary

How does Creative Medical Technology compare to KALA BIO?

Do insiders & institutionals have more ownership in CELZ or KALA?

Do analysts prefer CELZ or KALA?

Is CELZ or KALA more profitable?

Does the media refer more to CELZ or KALA?

Which has more risk and volatility, CELZ or KALA?

Which has preferable earnings and valuation, CELZ or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools